Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Shares of Altimmune ( NASDAQ: ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors ...

Travelling can be thrilling and overwhelming, especially when you’re managing a chronic condition like diabetes. The idea of ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

It seems like no matter what I do, I can’t lose weight. Most of my family members struggle with their weight too. Do our ...

Stopping GLP-1 RA treatment 14 days before total joint arthroplasty can minimize risks for complications, according to study findings.